Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis

J Comp Eff Res. 2022 Oct;11(14):1031-1044. doi: 10.2217/cer-2022-0074. Epub 2022 Aug 22.

Abstract

Introduction: Initial clinical manifestations of transthyretin amyloidosis (ATTR) are not well understood, making timely diagnosis challenging. Methods: Patients aged ≥68 years newly diagnosed with ATTR were identified using Medicare Research Identifiable Files. Symptom manifestation and healthcare utilization were measured during 3 years pre-diagnosis; demographics and comorbidity index during 1-year pre-diagnosis. Controls (ATTR-free) were matched 1:1 to patients with ATTR based on age, sex and region; same index date and enrollment as match. Results: We identified 552 matched ATTR-control pairs: mean age 78.3 (standard deviation 6.3) and 64.5% male. Among patients with ATTR (vs controls), cardiovascular conditions (92.9 vs 75.9%) and hospitalization (54.0 vs 35.5%) were frequent during 3 years pre-diagnosis. Conclusion: Patients with ATTR have multiple symptoms and hospitalizations pre-diagnosis, recognition of which may facilitate earlier diagnosis and treatment.

Keywords: Medicare; amyloid; health services research.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amyloid Neuropathies, Familial* / diagnosis
  • Amyloid Neuropathies, Familial* / therapy
  • Cardiomyopathies* / diagnosis
  • Female
  • Humans
  • Male
  • Medicare
  • Patient Acceptance of Health Care
  • United States

Supplementary concepts

  • Amyloidosis, Hereditary, Transthyretin-Related